我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

CYP2C19基因多态性与氯吡格雷抵抗的研究进展

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2014年第5期
页码:
603-606
栏目:
综述
出版日期:
2014-05-25

文章信息/Info

Title:
CYP2C19 polymorphism and clopidigrel resistance: research progress
作者:
石宇杰; 陈 菲; 金晶晶
(北京军区总医院心内科，北京100700)
Author(s):
SHI Yu-jie;  CHEN Fei;  JIN Jing-jing
(Department of Cardiology, General Hospital, Beijing Military Area Command, Beijing 100700, China)
关键词:
CYP2C19; 基因多态性; 氯吡格雷抵抗
Keywords:
CYP2C19;  gene polymorphism;  clopidogrel resistance
分类号:
R541.4;R972
DOI:
-
文献标识码:
A
摘要:
氯吡格雷是治疗急性冠脉综合征的一种经典抗血小板药物，但是临床观察到部分患者不能从氯吡格雷的治疗中获益，从而提出了氯吡格雷抵抗（CR）的问题。目前研究认为，CR受多因素影响，其中CYP2C19基因的多态性是最重要的内部因素。CYP2C19基因变异者，氯吡格雷的活性代谢产物减少，抗血小板效应减弱，不良心血管事件增加。而CYP2C19*2和CYP2C19*3是亚洲人最常见类型，因此，探讨CYP2C19基因的多态性对氯吡格雷疗效的影响具有临床意义。
Abstract:
Clopidogrel is a classic antiplatelet drug for acute coronary syndrome, but clinical observation shows that some patients do not benefit from clopidogrel therapy, and the issue of clopidogrel resistance (CR) is increased. CR is related to many possible factors and CYP2C19 polymorphism is one of the most important factors. Patients with genetic variants in CYP2C19 have been found to have lower levels of the active metabolites, less antiplatelet effect and a higher rate of major adverse cardiovascular events. Moreover, CYP2C19*2 and CYP2C19*3 are more common in Asian populations. Thus, study of the effect of CYP2C19 polymorphism on clopidogrel therapy is of clinical significance.

参考文献/References

[1]Holmes DR Jr,Dehmer GJ,Kaul S,et al.ACCF/AHA Clopidogrel clinical alert: approaches to the FDA“boxed warning”:a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association[J].Circulation,2010,122(5):537-557.
[2]Mega JL,Close SL,Wiviott SD,et al.Cytochrome p-450 polymorphisms and response to clopidogrel[J].N Engl J Med,2009,360(4):354-362.
[3]Shuldiner AR,O'Connell JR,Bliden KP,et al.Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy[J].JAMA,2009,302(8):849-857.
[4]Nasyuhana Sani Y,Sheau Chin L,Luen Hui L,et al.The CYP2C19 1/ 2 Genotype Does Not Adequately Predict Clopidogrel Response in Healthy Malaysian Volunteers[J].Cardiol Res Pract,2013,2013:128795.
[5]Lee JM,Park S,Shin DJ,et al.Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans[J].Am J Cardiol,2009,104(1):46-51.
[6]Simon T,Verstuyft C,Mary-Krause M,et al.Genetic determinants of response to clopidogrel and cardiovascular events[J].N Engl J Med,2009,360(4):363-375.
[7]Xie X,Ma YT,Yang YN,et al.CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population[J].PLoS One,2013,8(3):e59344.
[8]Zhang L,Chen Y,Jin Y,et al.Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients[J].Thromb Res,2013,132(1):81-87.
[9]Hulot JS,Collet JP,Silvain J,et al.Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration:a systematic meta-analysis[J].J Am Coll Cardiol,2010,56(2):134-143.
[10]Sibbing D,Koch W,Gebhard D,et al.Cytochrome 2C19*17 allelic variant,platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement[J].Circulation,2010,121(4):512-518.
[11]Tiroch KA,Sibbing D,Koch W,et al.Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events[J].Am Heart J,2010,160(3):506-512.
[12]Dai ZL,Chen H,Wu XY,et al.Relationship between cytochrome P450 2C19*17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel[J].Zhong Xi Yi Jie He Xue Bao,2012,10(6):647-654.
[13]Paré G,Mehta SR,Yusuf S,et al.Effects of CYP2C19 genotype on outcomes of clopidogrel treatment[J].N Engl J Med,2010,363(18):1704-1714.
[14]Frelinger AL 3rd,Bhatt DL,Lee RD,et al.Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms(CYP2C19.ABCB1, PON1), noncompliance,diet,smoking,co-medications(including proton pump inhibitors),and pre-existent variability in platelet function[J].J Am Coll Cardiol,2013,61(8):872-879.
[15]Mehta SR,Tanguay JF,Eikelboom JW,et al.Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial[J].Lancet,2010,376(9748):1233-1243.
[16]Patti G,Bárczi G,Orlic D,et al.Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study[J].J Am Coll Cardiol,2011,58(15):1592-1599.
[17]Solmaz H,Akbulut M,Korkmaz H,et al.Effects of high loading dose of clopidogrel in ST elevated myocardial infarction treated with fibrinolytic agent[J].Clin Invest Med,2013,36(1):E18-E23.
[18]Price MJ,Berger PB,Teirstein PS,et al.Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial[J].JAMA,2011,305(11):1097-1105.
[19]Bonello-Palot N,Armero S,Paganelli F,et al.Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention[J].Am J Cardiol,2009,104(11):1511-1515.

备注/Memo

备注/Memo:
收稿日期：2013-12-23.
作者简介：石宇杰，主治医师，博士生 Email:175547929@qq.com
更新日期/Last Update: 2014-06-05